PACB director granted 223,492 stock options

PACIFIC BIOSCIENCES OF CALIFORNIA director Christopher M. Smith received a grant of stock options covering 223,492 shares of common stock.

Rhea-AI Filing Summary

PACIFIC BIOSCIENCES OF CALIFORNIA director Christopher M. Smith received a grant of stock options covering 223,492 shares of common stock. The options have an exercise price of $1.58 per share, expire on June 3, 2036, and vest monthly over one year while he continues serving as a director. Following this grant, he holds options on 223,492 shares directly.

Insider Trade Summary

Grant/Award: 223,492 shares

Grant/Award 1 txn

Insider Smith Christopher M

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	223,492	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 223,492 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option will vest monthly over one (1) year, on the same day of the month as the date of grant or, if earlier, on the date of the next annual meeting of the Company's stockholders occurring after the date of grant, provided such Reporting Person continues to serve as a director through the applicable vesting dates.

Key Figures

Option grant size: 223,492 shares Exercise price: $1.58 per share Expiration date: June 3, 2036 +2 more

5 metrics

Option grant size 223,492 shares Stock options on PACB common stock granted to director

Exercise price $1.58 per share Conversion or exercise price of stock options

Expiration date June 3, 2036 Option expiration for director grant

Post-transaction options 223,492 shares Total derivative shares following transaction

Vesting period 1 year monthly Options vest monthly over one year while serving as director

Key Terms

Stock Option (right to buy), Grant, award, or other acquisition, exercise price, vest monthly, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

exercise price financial

"conversion_or_exercise_price: 1.5800"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest monthly financial

"The shares subject to the option will vest monthly over one (1) year"

derivative securities financial

"derivativeTransactionCount: 1 derivative-type record reported"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did PACB director Christopher M. Smith report in this Form 4?

Christopher M. Smith reported receiving a grant of stock options for 223,492 PACB common shares. These options were awarded as compensation and are classified as a grant or award acquisition, not an open-market purchase or sale of the company’s stock.

How many PACB shares are covered by Christopher M. Smith’s new stock options?

The new stock option grant covers 223,492 shares of PACB common stock. This entire amount is reported as directly owned derivative securities following the transaction, reflecting his full option position from this award alone in the current filing.

What is the exercise price and expiration date of Christopher M. Smith’s PACB options?

The options have an exercise price of $1.58 per share and expire on June 3, 2036. This means Smith can, once vested, buy PACB common stock at $1.58 per share any time before the June 2036 expiration date.

How do Christopher M. Smith’s PACB options vest over time?

The options vest monthly over one year on the same calendar day as the grant date. Vesting continues only while Smith serves as a director, or until the next annual stockholders’ meeting if that occurs earlier, according to the disclosed vesting footnote.

Did Christopher M. Smith buy or sell PACB shares in the market?

He did not report any open-market buys or sells of PACB shares. The Form 4 shows a single derivative transaction coded as a grant or award acquisition, reflecting stock option compensation rather than market trading activity in PACB’s common stock.

What are Christopher M. Smith’s PACB derivative holdings after this transaction?

After this transaction, Smith directly holds stock options covering 223,492 PACB common shares. The filing’s summary shows this entire amount as his post-transaction derivative position, with no additional remaining derivative positions listed in the derivative summary table.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/04/2026 - 05:25 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Smith Christopher M

(Last) (First) (Middle)

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

1305 O'BRIEN DRIVE

(Street)

MENLO PARK CALIFORNIA 94025

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. [ PACB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.58	06/03/2026		A		223,492		07/03/2026(1)	06/03/2036	Common Stock	223,492	$0	223,492	D

Explanation of Responses:

1. The shares subject to the option will vest monthly over one (1) year, on the same day of the month as the date of grant or, if earlier, on the date of the next annual meeting of the Company's stockholders occurring after the date of grant, provided such Reporting Person continues to serve as a director through the applicable vesting dates.

Remarks:

	/s/ Brett Atkins, Attorney-in-fact	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)